8-K: Bicycle Therapeutics Holds Annual Shareholder Meeting
Annual General Meeting Results
Bicycle Therapeutics plc announced that all proposals, including director re-elections and auditor ratification, were approved at its annual general meeting on June 17, 2026.
Summary
- Bicycle Therapeutics plc held its annual general meeting (AGM) on June 17, 2026.
- All nine proposals presented to shareholders were passed on a poll vote.
- Key approvals included the re-election of directors Felix Baker and Herv Hoppenot.
- Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm and U.K. statutory auditors for the year ending December 31, 2026.
- The compensation of named executive officers was approved on an advisory basis.
- The company's U.K. statutory annual accounts and reports for the year ended December 31, 2025, were adopted.
- The directors remuneration report and the directors remuneration policy were also approved.
- Approximately 98.64% of the issued and outstanding ordinary shares were represented at the AGM.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive filing due to the strong shareholder turnout and unanimous approval of all proposals, indicating stable governance and shareholder alignment.
Positives
- Strong shareholder turnout with approximately 98.64% of shares represented.
- Unanimous approval of all nine proposals put forth at the AGM.
- Re-election of key directors Felix Baker and Herv Hoppenot.
- Ratification of PricewaterhouseCoopers LLP as independent auditors and U.K. statutory auditors.
- Advisory approval of executive compensation.
- Adoption of 2025 annual accounts and reports.
- Approval of directors remuneration report and policy.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing, which pertains to the results of the annual general meeting.
Industry Context
StockSavvy.ai notes that the smooth execution of annual general meetings with high shareholder participation and unanimous approval of routine matters, such as director re-elections and auditor appointments, is generally viewed positively by the market as it indicates stable corporate governance and shareholder confidence.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Felix Baker | Felix Baker | 2026-06-17 | Re-election |
| Director | Herv Hoppenot | Herv Hoppenot | 2026-06-17 | Re-election |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Re-election | Re-election of Felix Baker as a director. | 2026-06-17 | Maintains continuity in board leadership. |
| Director Re-election | Re-election of Herv Hoppenot as a director. | 2026-06-17 | Maintains continuity in board leadership. |
| Auditor Appointment Ratification | Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. | 2026-06-17 | Ensures continued independent financial oversight. |
| Auditor Re-appointment | Re-appointment of PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors. | 2026-06-17 | Ensures continued statutory audit compliance. |
| Auditor Remuneration Authorization | Authorization for the Audit Committee to determine the Company's U.K. statutory auditors remuneration for the year ending December 31, 2026. | 2026-06-17 | Grants oversight of auditor fees to the Audit Committee. |
| Advisory Vote on Executive Compensation | Approval, on an advisory basis, of the compensation of the Company's named executive officers. | 2026-06-17 | Provides shareholder feedback on executive pay. |
| Adoption of Financial Statements | Receipt and adoption of the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025. | 2026-06-17 | Formal acceptance of the company's past financial performance. |
| Approval of Directors Remuneration Report | Approval of the directors remuneration report for the year ended December 31, 2025. | 2026-06-17 | Shareholder endorsement of disclosed director compensation practices. |
| Approval of Directors Remuneration Policy | Approval of the directors remuneration policy. | 2026-06-17 | Sets the framework for future director compensation. |
Stakeholder Impact
- Shareholders: Re-election of directors and approval of compensation policies affirm current governance and executive pay structures.
- Auditors: Continued engagement of PricewaterhouseCoopers LLP provides stability in financial auditing.
- Management: Advisory approval of executive compensation indicates shareholder confidence in current remuneration practices.
Key Dates
| Date | Description |
|---|---|
| 2019-05-28 | Date of the deposit agreement by and among the Company, Citibank, N.A., as depositary, and holders and beneficial owners of American Depositary Shares (ADSs). |
| 2025-12-31 | Year ended December 31, 2025, for which the company's U.K. statutory annual accounts and reports were adopted. |
| 2026-04-22 | Date the Company's definitive proxy statement on Schedule 14A was filed with the Securities and Exchange Commission. |
| 2026-06-17 | Date of the annual general meeting of shareholders (AGM) and date of report. |
| 2026-12-31 | Year ending December 31, 2026, for which PricewaterhouseCoopers LLP was appointed as independent registered public accounting firm and U.K. statutory auditors. |
| 2026-06-18 | Date the report was signed. |
Recommendation
holdThe filing reports on routine annual general meeting matters with all proposals passing, indicating stable governance. However, it does not contain new financial performance data, strategic updates, or significant forward-looking guidance that would warrant a change in investment recommendation.
Keywords
Bicycle Therapeutics, AGM, Shareholder Meeting, Director Re-election, Auditor Ratification, Corporate Governance, Annual Report, Proxy Statement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.